| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash provided by financing activities | 129,509 | 14,652 |
| Net increase (decrease) in cash, cash equivalents and restricted cash equivalents | 4,555 | -32,662 |
| Cash and cash equivalents at beginning of period | 202,787 | - |
| Cash and cash equivalents at end of period | 207,342 | - |
Intellia Therapeutics, Inc. (NTLA)
Intellia Therapeutics, Inc. (NTLA)